First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial
Clinical Lymphoma Myeloma and Leukemia · 2026-11
DOI: 10.1016/j.clml.2026.10.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Tian Wang und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, T., Liu, X., Wang, J., Tang, T., Wang, W., Wang, X., Song, X., & Ding, H. (2026). First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.025
Vancouver
Wang T, Liu X, Wang J, Tang T, Wang W, Wang X, et al. First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.025
BibTeX
@article{Wang2026,
author = {Wang, Tian and Liu, Xiang and Wang, Jie and Tang, Tianci and Wang, Weifang and Wang, Xiaoshen and Song, Xinmao and Ding, Hao},
title = {First-line tislelizumab, pegaspargase, and gemcitabine with consolidative radiotherapy for early-stage extranodal NK/T-cell lymphoma: a single-arm, phase II trial},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.10.025}
}
EUVIMED